Treating Lung Cancer with a New Combination of Medications

Recruiting · Phase 1 · Extensive-stage Small-cell Lung Cancer · New Jersey and New York

Check if I qualify View on ClinicalTrials.gov

About this trial

This study looks at the safety of using valemetostat along with atezolizumab for people with extensive-stage small cell lung cancer (SCLC). Researchers will try different doses of valemetostat to find the highest dose that causes few or mild side effects. After that, they will check the safety and effectiveness of this treatment in a new group of participants.

The trial's ID number is NCT06807632. It is a Phase 1 study, which means it is looking at how safe the treatment is and how well it works. This study is FDA-regulated and hopes to include 24 participants.

Who can join

This trial is open to adults aged 18 and older. Both men and women can join. Participants must have extensive-stage small cell lung cancer and be able to start treatment within four weeks of finishing their last chemotherapy. The team will check who can participate based on specific health criteria.

Condition

Extensive-stage Small-cell Lung Cancer

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Everyone in the study will receive valemetostat and atezolizumab. The treatment starts with valemetostat at a dose of 150 mg taken once daily, along with atezolizumab given every four weeks. This trial has two phases: one to find the right dose and another to learn more about the treatment's effects.